13D Filing: Biotechnology Value Fund LP and BioLineRX Ltd. (BLRX)

Page 13 of 15

Page 13 of 15 – SEC Filing

Other than as described
herein, there are no contracts, arrangements, understandings or relationships among the Reporting Persons, or between the Reporting
Persons and any other person, with respect to the securities of the Issuer.

Item 7. Material to be Filed as Exhibits.
99.1 Subscription Agreement by and among Biotechnology Value Fund, L.P., Biotechnology Value Fund II,
L.P., Biotechnology Value Trading Fund OS LP, BVF Partners OS Ltd., BVF Partners L.P through certain of its managed accounts and
BioLineRx Ltd., dated July 26, 2017.
99.2 Voting and Standstill Agreement by and among Biotechnology Value Fund, L.P., Biotechnology Value
Fund II, L.P., Biotechnology Value Trading Fund OS LP, BVF Partners OS Ltd., BVF Partners L.P through certain of its managed accounts
and BioLineRx Ltd., dated July 26, 2017
99.3 Joint Filing Agreement by and among Biotechnology Value Fund, L.P., Biotechnology Value Fund II,
L.P., Biotechnology Value Trading Fund OS LP, BVF Partners OS Ltd., BVF Partners L.P., BVF Inc. and Mark N. Lampert, dated August
7, 2017.
13

Follow Biolinerx Ltd. (NASDAQ:BLRX)

Page 13 of 15